Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

[Second Half] Integrated Report "ASKA_HD_REPORT_2026"

Following approval at the annual general meeting of shareholders held in June 2026, the company transitioned from a company with a board of corporate auditors to a company with an audit and supervisory committee. From fiscal 2026, it also revised its shareholder return policy, setting a total payout ratio of 40% as a guideline and introducing progressive dividends.

Worth reading
80Important
Scored from 2 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
40
Total payout ratio (%)
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee1
ESG Committee . The ESG Committee is a voluntary advisory body independent of the Board of Directors.
Policy on cross-shareholdings

The company is continuously reducing non-operating assets, including idle assets, with a focus on cross-held shares. Number of holdings and amount: Not disclosed

Policy regarding shares of other companies held to maintain business relationships and for other purposes.

Changes this time

Following approval at the annual general meeting of shareholders held in June 2026, the company transitioned to a company with an audit and supervisory committee. From fiscal 2026, it changed its shareholder return policy, introducing returns with a total payout ratio of 40% as a guideline and progressive dividends.

Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeESG Committee (proportion of outside members: Not disclosed). The ESG Committee is a voluntary advisory body independent of the Board of Directors.
Policy on cross-shareholdingsThe company is continuously reducing non-operating assets, including idle assets, with a focus on cross-held shares. Number of holdings and amount: Not disclosed
Changes this timeFollowing approval at the annual general meeting of shareholders held in June 2026, the company transitioned to a company with an audit and supervisory committee. From fiscal 2026, it changed its shareholder return policy, introducing returns with a total payout ratio of 40% as a guideline and progressive dividends.
Items this document does not state (4)
Number of directorsNumber of independent officersTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Investors expressed views calling for a higher proportion of outside directors, separation of executive functions from oversight and shorter directors’ terms of office. After discussion by the Board of Directors and approval at the annual general meeting of shareholders, the company transitioned to a company with an audit and supervisory committee. The revision of the shareholder return policy is intended to clarify its approach to profit returns in line with Medium-Term Management Plan 2028 and maintain stable dividends.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
[Second Half] Integrated Report "ASKA_HD_REPORT_2026" | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori